Powder: -20°C for 3 years | In solvent: -80°C for 1 year
A novel combination of triterpenoids includes at least ganoderic acid S (GAS), ganoderic acid T (GAT), ganoderic acid Me (GAMe), ganoderic acid R (GAR), and ganodermic acid S (GMAS), the composition is suitable for the treatment or prophylaxis of colon cancer, hepatic cancer, breast cancer, lung cancer or leukemia. Ganoderic acid S and Mf induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 660.00 | |
1 mL * 10 mM (in DMSO) | Inquiry | $ 670.00 |
Description | A novel combination of triterpenoids includes at least ganoderic acid S (GAS), ganoderic acid T (GAT), ganoderic acid Me (GAMe), ganoderic acid R (GAR), and ganodermic acid S (GMAS), the composition is suitable for the treatment or prophylaxis of colon cancer, hepatic cancer, breast cancer, lung cancer or leukemia. Ganoderic acid S and Mf induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. |
Molecular Weight | 452.679 |
Formula | C30H44O3 |
CAS No. | 104759-35-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ganoderic acid S 104759-35-5 Others inhibitor inhibit